Are you an EPFL student looking for a semester project?
Work with us on data science and visualisation projects, and deploy your project as an app on top of Graph Search.
Cellestia Biotech SA is a Swiss biopharmaceutical company focused on pioneering innovative therapeutics for autoimmune diseases and multi-drug resistant cancers. Their lead compound, CB-103, targets the CSL-NOTCH transcription complex, addressing unmet medical needs by developing first-in-class therapies. With a strong emphasis on patient dedication, Cellestia aims to extend and improve the quality of life for patients with limited treatment options. By overcoming dose-limiting toxicities associated with NOTCH inhibitors, Cellestia's approach holds promise in the oncology and autoimmune markets. With an Investigational New Drug (IND) approval in place, CB-103 is set to enter Proof-of-Concept clinical studies for graft-versus-host disease (GvHD), with successful Phase 2 trials demonstrating efficacy in treating patients with multi-drug resistant cancers. Additionally, Cellestia is advancing a range of pre-clinical candidates for chronic autoimmune indications, positioning itself to bring innovative therapies to patients across various medical needs.
Freddy Radtke, Ute Koch, Catherine Michelle Hoffman
, , , , , , , ,